Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins

Paola Sarchielli, M. Zaffaroni, A. Floridi, L. Greco, A. Candeliere, A. Mattioni, S. Tenaglia, M. Di Filippo, P. Calabresi

Research output: Contribution to journalArticlepeer-review

Abstract

Sixty, relapsing remitting (RR) multiple sclerosis (MS) patients, who underwent treatment with glatiramer acetate (GA), interferon (IFN)-β 1a, and immunoglobulins (Igs) (20 per treatment group), were assessed for levels of brain-derived neurotrophic factor (BDNF) in the supernatants of unstimulated and stimulated peripheral blood mononuclear cells (PBMCs) in the first year of treatment. Phytohemagglutinin (PHA), anti-OKT3 antibody, myelin basic protein (MPB) and GA were used as stimuli. Cytokine responses by ELISPOT and lymphoproliferative responses were also assessed. The GA-treated MS patient group showed a progressive increase in BDNF levels, from baseline to month three; thereafter, the levels remained stable and significantly greater compared with baseline and controls (ANOVA=P

Original languageEnglish
Pages (from-to)313-331
Number of pages19
JournalMultiple Sclerosis Journal
Volume13
Issue number3
DOIs
Publication statusPublished - Apr 2007

Keywords

  • Brain-derived neurotrophic factor
  • Glatiramer acetate
  • Immunoglobulins
  • Interferon-beta 1a
  • Multiple sclerosis
  • Peripheral blood mononuclear cells

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins'. Together they form a unique fingerprint.

Cite this